Clinical trial
17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating…
NCT00248521 · Institute of Cancer Research, United Kingdom, Other · Unknown status
Key facts
| NCT number | NCT00248521 |
|---|---|
| Title | 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery |
| Official title | A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors |
| Lead sponsor | Institute of Cancer Research, United Kingdom, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | alvespimycin hydrochloride |
| Enrollment | 35 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2007 |
| First posted | Nov 4, 2005 |
| Last update posted | Aug 2, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: